Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia

Constance Baer, Wolfgang Kern, Sarah Koch, Niroshan Nadarajah, Sonja Schindela, Manja Meggendorfer, Claudia Haferlach, and Torsten Haferlach

Disclosures: This research was supported by a grant from ARIAD Pharmaceuticals to WK and TH. The opinions expressed in this paper are those of the authors and do not necessarily represent those of ARIAD Pharmaceuticals. C.B., S.K., N.N., M.M., S.S.: Employment by MLL Munich Leukemia Laboratory; W.K., C.H., T.H.: Equity ownership of MLL Munich Leukemia Laboratory. C.B., W.K., T.H. served for the Ariad advisory committee.

Contributions: Contribution: C.B., S.K. and S.S. performed experiments; C.B. and N.N. analyzed results; C.B., W.K., M.M., C.H. and T.H. designed the research and wrote the paper.